ArticleThe Journal of pathology2026
Deep learning-based H&E-derived risk scores in colorectal cancer: associations with tumour morphology, biology, and predicted drug response.
Article in The Journal of pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Methylation-Associated Differentiation Features Define Biological and Prognostic Heterogeneity in CMS4 Colorectal Cancer.International journal of molecular sciences · 2026Article
- V7-DiVA: a feature-based Deep MIL colorectal whole-slide histopathology research platform with blinded external image-input validation.Journal of translational medicine · 2026Article
- Predicting protein cascade expression from H&E images.PLoS computational biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Funding
Abstract
Over recent years, several deep learning (DL) models have been presented to predict colorectal cancer (CRC) patient survival directly from haematoxylin and eosin (H&E)-stained routine whole-slide images (WSIs). Unlike traditional studies that rely on manually defined histopathological features, weakly supervised DL allows training directly on clinical endpoints without prior specification of the model's focus. This offers a unique opportunity to study the tissue morphology underlying these predictions, improving our understanding of disease biology. Here, we present a comprehensive analysis of the clinicopathological features, tumour morphology and biology, as well as gene expression-based predicted drug response of over 4,000 CRC patients derived from four different international cohorts with available H&E-inferred DL-based risk scores (low- versus high-risk as well as absolute risk scores). The results from our study suggest that conventional clinicopathological risk factors, such as grade of differentiation, presence of lymph node metastasis, tumour budding, and percentage of tumour necrosis, are positively associated with DL-based risk scores. Moreover, CRCs with direct tumour-adipocyte interactions are enriched in the DL-based high-risk group. Through detailed morphologic review, we provide comprehensive evidence that direct tumour-adipocyte interaction, a high degree of tumour budding, and poorly differentiated morphology are linked to high DL-based risk scores. Transcriptomic and genetic subgroups show only limited association with H&E-derived DL-based risk scores. Moreover, we present data suggesting that DL-based low- versus high-risk CRCs may be characterised by differential drug sensitivity. Our study highlights that DL-based risk scores derived from H&E WSIs not only align with established clinicopathological features but also highlight morphological features, such as tumour-adipocyte interaction, that are not routinely captured by established clinicopathological scoring systems. Moreover, DL-based risk groups may be associated with a differential treatment response, underlining their potential to guide patient stratification in routine clinical practice. © 2026 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.